Celgene Flexes Its Muscles
By
Alex Lash / Email the Author / IN VIVO March 2011, Vol. 29, No. 3
Feature Articles / Word Count: 4073 / Article # 2011800040
Executive Summary
In five short years, Celgene has used the cash from the blockbuster success of its flagship product Revlimid to pursue a wide range of deals for revenues now and new markets later. Its homegrown R&D has created a bountiful late-stage pipeline. It’s projecting even more Revlimid success in the next few years. So why aren’t investors buying?
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.